HER2 Interactome Profiling Reveals MARCKS as a Candidate Marker Associated with Aggressive Breast Cancer
Cancers · 02.09.2025 · 17 (17) · 2882
DOI: 10.3390/cancers17172882 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancers, online erschienen am 02.09.2025. Verfasst von Atsushi Yokoyama und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Endocrinology, Tohoku University Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai 980-8575, Japan. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science, Institute of Advanced Medical Sciences, Tokushima University, Suzuken (Japan).
Abstract (Originalsprache)
Background/Objectives: HER2, a critical diagnostic marker and therapeutic target in breast cancer, is a membrane receptor that forms diverse signaling complexes, the constituents of which have not been fully characterized in actual breast cancer tissues.
Methods
In this study, we applied the Rapid Immunoprecipitation Mass Spectrometry of Endogenous Proteins (RIME) method, originally developed to explore transcription factor complexes, to identify the complexes formed by HER2 in HER2-positive breast cancer specimens.
Results
Through our approach, we successfully identified multiple complex components, including MARCKS, a novel HER2-interacting partner, which we verified using both proximal ligation assay in cultured cells and immunohistochemistry in tissue sections. TCGA analysis further revealed that high MARCKS expression significantly correlates with ER negativity, as confirmed by multivariate analysis, suggesting its potential role as a prognostic indicator in aggressive breast cancer subtypes.
Conclusions
These results demonstrate the capability of RIME to elucidate interactomes of membrane proteins such as HER2 in clinical tissue specimens. Furthermore, this study highlights its broader applicability beyond nuclear proteins, underscoring its potential for discovering novel prognostic and diagnostic clinical markers in diverse cancer types.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Molecular Endocrinology, Tohoku University Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai 980-8575, Japan.
- Research and Innovation Liaison Office, Institute of Advanced Medical Sciences, Tokushima University, 3-18-15 Kuramoto-cho, Tokushima 770-8503, Japan.
- Department of Breast and Endocrine Surgical Oncology Graduate School of Medicine Tohoku University, 1-1 Seiryo-machi, Aoba-ku, Sendai 980-8574, Japan.
- Department of Anatomic Pathology, Tohoku University Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai 980-8575, Japan.
ORCID-Profile: Atsushi Yokoyama, Shun Sawatsubashi, Akiko Ebata, Yasuhiro Miki, Takashi Suzuki
Förderung
- Japan Society for the Promotion of Science
- Institute of Advanced Medical Sciences, Tokushima University
- Suzuken (Japan)
- Japan Society for the Promotion of Science (JSPS) KAKENHI
- Joint Usage and Joint Research Programs, the Institute of Advanced Medical Sciences, Tokushima University
- Suzuken Memorial Foundation
Zitieren
APA
Yokoyama, A., Sawatsubashi, S., Ebata, A., Miki, Y., Otsubo, Y., & Suzuki, T. (2025). HER2 Interactome Profiling Reveals MARCKS as a Candidate Marker Associated with Aggressive Breast Cancer. Cancers, 17(17), 2882. https://doi.org/10.3390/cancers17172882
Vancouver
Yokoyama A, Sawatsubashi S, Ebata A, Miki Y, Otsubo Y, Suzuki T. HER2 Interactome Profiling Reveals MARCKS as a Candidate Marker Associated with Aggressive Breast Cancer. Cancers. 2025;17(17):2882. doi:10.3390/cancers17172882
BibTeX
@article{Yokoyama2025,
author = {Yokoyama, Atsushi and Sawatsubashi, Shun and Ebata, Akiko and Miki, Yasuhiro and Otsubo, Yuri and Suzuki, Takashi},
title = {HER2 Interactome Profiling Reveals MARCKS as a Candidate Marker Associated with Aggressive Breast Cancer},
journal = {Cancers},
year = {2025},
volume = {17},
number = {17},
pages = {2882},
doi = {10.3390/cancers17172882}
}
EUVIMED